<DOC>
	<DOCNO>NCT03092882</DOCNO>
	<brief_summary>The Digital Self-Management Program Medicare Advantage Members Type 2 Diabetes - Impact A1c trial 26-week long , prospective , intent-to-treat , 2-arm randomize controlled trial aim evaluate impact Digital Self-Management Program A1c level individual uncontrolled Type 2 diabetes .</brief_summary>
	<brief_title>Digital Self-Management Program Medicare Advantage Members With Type 2 Diabetes- Impact A1c</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Imidacloprid</mesh_term>
	<criteria>Humana Medicare Advantage member Type 2 diabetes diagnosis HbA1c level â‰¥ 8.0 % verified lab test Has follow condition : cancer , chronic heart failure , chronic obstructive pulmonary disease , respiratory failure , chronic kidney disease , end stage renal disease , peripheral vascular disease Not fluent English Humana membership part Full Global risk arrangement Enrolled Humana Home Care Management</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>